A Phase 3 interventional study of estrace cream (Perrigo) and estrace cream (Reference) in Atrophy, sponsored by Padagis LLC. Completed at 1 site in United States. Open to female participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-11-02.
Sponsored by Padagis LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Atrophy with a site in United States — 6 open to participants now, 8 under way, 1 of them phase 3. Atrophy · United States.
Among the 29 studies in Atrophy with a site in United States, this one has the largest enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2016, is one of 4 in phase 3, and was the 13th registered.
126 studies on the registry are indexed under Atrophy; 22 are open to participants now.
Browse Atrophy studies →6 of the 29 studies in Atrophy with a site in United States are open now. Recruiting first, the newest first:
Kalpna Kay Durairaj, MD, FACS · Sites in United States
Ages 21–65
Hebrew SeniorLife · Sites in United States, Israel
Ages 65–90
Carl Zeiss Meditec-Dublin CoCe · Sites in United States
Ages 18+ · Healthy volunteers
University of Kansas Medical Center · Sites in United States
Ages 18–45 · Women only
University of Oregon · Sites in United States
Ages 18–80 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Atrophy studies recruiting now, 5 (36%) set no upper age limit and 4 (29%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.
This study: 30 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 695 is above the median of 36 across 105 interventional studies indexed under Atrophy.
Median enrollment 42 across the 24 interventional studies, 13 across the 5 observational. Of the 19 that completed or were terminated, 4 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 29 have an industry lead sponsor. The 10 most frequent:
Padagis LLC is the lead sponsor of 37 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Padagis LLC has 1 study filed under Atrophy — fewer than ten, so there is no comparison to draw.
2 of the studies in Atrophy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05926219University of OregonC-Protein in Fatigue and Aging | 2027-01 |
| NCT07419854Kalpna Kay Durairaj, MD, FACSRestoring Facial Volume After GLP-1 Weight Loss With Radiesse | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Atrophy with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare safety and efficacy of Perrigo's drug product compared to an FDA approved drug product in the treatment of vulvar and vaginal atrophy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has deep vein thrombosis, pulmonary embolism or history of these conditions.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
estradiol cream
Drug: estrace cream (Perrigo)
estradiol cream
Drug: estrace cream (Reference)
Placebo cream
Drug: Placebo cream
Also known as: Perrigo product
Also known as: Reference Listed Drug product
Percentage of Subjects Identified as Responders
A responder is a subject meeting specific vaginal cytology criteria AND a vaginal pH \< 5.0 with a change from Visit 1 of at least 0.5.
Time frame: Day 8
Most Bothersome Symptom
Percentage of subjects based on the improvement (change from Visit 2) of the Most Bothersome Symptom at Visit 3.
Time frame: Day 8
| Milestone | Test Product | Reference Product | Placebo Product |
|---|---|---|---|
| Started | 277 | 279 | 139 |
| Completed | 272 | 275 | 139 |
| Not completed | 5 | 4 | 0 |
A responder is a subject meeting specific vaginal cytology criteria AND a vaginal pH \< 5.0 with a change from Visit 1 of at least 0.5.
| percentage of responders | Test Product | Reference Product | Placebo Product |
|---|---|---|---|
| Percentage of Subjects Identified as Responders | 36.8 | 32.0 | 0.8 |
Percentage of subjects based on the improvement (change from Visit 2) of the Most Bothersome Symptom at Visit 3.
| Participants | Test Product | Reference Product |
|---|---|---|
| Most Bothersome Symptom | 116 | 123 |
Collected over 8 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test Product | 0/277 (0%) | 0/277 (0%) | 0/277 (0%) |
| Reference Product | 0/279 (0%) | 0/279 (0%) | 0/279 (0%) |
| Placebo Product | 0/139 (0%) | 0/139 (0%) | 0/139 (0%) |
| Age, Continuous(years) | Test Product | Reference Product | Placebo Product | Total |
|---|---|---|---|---|
| Mean | 60.3 ± 6.35 | 59.9 ± 6.31 | 59.2 ± 6.06 | 59.9 ± 6.28 |
| Sex: Female, Male(Participants) | Test Product | Reference Product | Placebo Product | Total |
|---|---|---|---|---|
| Female | 275 | 277 | 139 | 691 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Test Product | Reference Product | Placebo Product | Total |
|---|---|---|---|---|
| Hispanic or Latino | 55 | 59 | 29 | 143 |
| Not Hispanic or Latino | 220 | 218 | 110 | 548 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Test Product | Reference Product | Placebo Product | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 8 | 5 | 0 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 33 | 35 | 25 | 93 |
| White | 233 | 235 | 114 | 582 |
| More than one race | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of May 2016, a primary completion of Nov 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2020, 3 years 9 months after primary completion. A results delay was requested in Dec 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Estradiol